The GLP-1 Frenzy: Lessons from the Market – The Need for Regulation and Cooling Down

The initial surge of interest in GLP-1 drugs in early 2026 has sent shockwaves through the investment market, raising concerns that a similar speculative bubble reminiscent of past technological booms is being replicated. According to CNBC reports, this rapid price volatility reflects investors’ speculative psychology and could undermine the healthy development of the market. This report aims to identify the risks of the initial GLP-1 drug frenzy and draw insights for investment strategy formulation.

The Context of the Initial Frenzy: Technological Expectations and Investor Psychology

The surge in interest in GLP-1 drugs is believed to be driven by expectations of innovative therapeutic effects, combined with the influence of past successful technological investment cases. Specifically, the potential growth of the obesity treatment market and investors’ high willingness to take risks have acted in combination to create a speculative atmosphere. According to CNBC reports, early investors, fueled by the expectation of short-term high returns, rushed into investment without sufficient due diligence.

Signs of Speculative Bubble

The initial frenzy quickly escalated into a speculative bubble. The stock price rose regardless of objective indicators such as drug development stages, clinical trial results, and market competition. This was a phenomenon driven by psychological factors among market participants, with investors increasingly aggressive investment driven by FOMO (Fear Of Missing Out).

Lessons from the Market: The Need for Regulation

The GLP-1 drug market case can be interpreted as a warning signal for the speculative overheating phenomenon appearing across the entire market today. Like past technological bubbles, excessive expectations and speculative psychology can ultimately lead to market collapse. Therefore, appropriate regulation and supervision are needed to ensure the healthy development of the market.

Directions for Regulation

First, strengthening the obligation to disclose information is necessary to protect investors. Information that could affect investment decisions, such as drug development stages, clinical trial results, and market competition, should be transparently disclosed. In addition, monitoring and punishing unfair trading practices and market manipulation should be strengthened. Finally, improving investors’ risk management capabilities through investor education is also important.